Technology born from world-class nanoscience

Disruptive Pharma is rooted in nanoscience research conducted at Uppsala University, where work led by Professor Maria Strömme resulted in the discovery of a novel nanostructured, amorphous magnesium carbonate material (MMC).

A first patent application was filed in 2012, forming the basis for Disruptive Materials. To fully focus on pharmaceutical applications, Disruptive Pharma was established in 2021 as a spin-out, dedicated to developing and commercializing the Formulite^™technology platform.

Scientific validation

The Formulite^™platform has demonstrated feasibility across more than 100 APIs, with over 20 compounds evaluated in pharmacokinetic (PK) studies, supporting the platform’s broad applicability and performance. The technology is underpinned by published research describing the physicochemical properties of mesoporous magnesium carbonate, its ability to stabilize amorphous drugs, and its impact on dissolution and bioavailability.

Selected publications
Frykstrand et al 2014 – Pore forming mechanism of MMC
Zhang et al 2014 – Stabilization of amorphous ibuprofen in MMC
Zhang et al 2016 – Controlled Drug Release from MMC
Zhang Thesis 2016 – MMC as a drug delivery vehicle for stabilizing amorphous drugs and regulating their release rate
Gomez de la Torre et al 2022 – Bioavailability of Celecoxib in MMC, An In Vivo Evaluation
Katsiotis et al 2024 – Development of a simple paste for 3D printing

A bright future

By building a strategic a pipeline of proprietary formulations of oral small molecule drugs, primarily within the oncology area, we will showcase the Formulite^™ and bring it to the market. In this effort we offer various opportunities for partnerships and licensing agreements with both biotech and pharma companies.

We see a large potential in providing the best solutions for our partners to get the most out of their assets and turn them into commercially viable therapeutic drug products. Formulite^™ can be used to extend and manage lifecycle of existing products based on crystalline formulation of drugs with poor water solubility. Our R&D team has established a streamlined process which reduces the effective development time for future products in our pipeline. The future looks bright!